Advicenne: Paris Commercial Court extends safeguard period by six months, until May 2027
The Paris Commercial Court has granted Advicenne six additional months under its safeguard proceedings. The observation period now runs until May 5, 2027, the laboratory said in a press release published on November 17, 2026.
A hearing on November 9 and a deadline pushed back to May 2027
The decision was handed down at the hearing held on November 9, 2026 before the Paris Commercial Court. In a press release dated November 3, 2026, the company had presented this hearing as the one marking the end of the observation period of its safeguard proceedings.
At the close of this hearing, the court did not end this phase: it extended it. The company, listed on Euronext Growth Paris, therefore remains under safeguard proceedings until the new deadline.
Sibnayal, flagship product of a laboratory under court protection
Advicenne stated that it will continue to regularly communicate on the various developments in the proceedings. Founded in 2007 and based in Paris, the laboratory develops treatments in nephrology.
Its main product, Sibnayal (ADV7103), holds a marketing authorization for distal renal tubular acidosis in the European Union, the United Kingdom, Saudi Arabia and the United Arab Emirates. It is marketed in more than twenty-five countries in Europe.
Listed in Paris since 2017, Advicenne shares were transferred to Euronext Growth Paris on March 30, 2022.
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
SectorPharmacie et biotechnologies›Biotechnologies
Context
Period
Period: S1 2026
Key reported figures
Revenue: 2,9 millions d'euros
Quarterly revenue: 2,9 millions d'euros
Revenue growth: 3,5 %
Net income: 4,6 millions d'euros
25,5 millions d'euros
Risks mentioned
L'impact de l'accès facilité aux traitements est incertain.
Les résultats peuvent différer des projections à cause des risques de marché.
Opportunities identified
Les ventes de Sibnayal® continuent de progresser avec des croissances significatives.
Le remboursement de Likozam® contribue à une forte croissance des ventes.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.